Vasomotor symptom (VMS) management with non-hormonal options
This webinar is targeted at GPs, specialists and allied health workers who are seeking a comprehensive update on non-hormonal therapies for VMS. Although menopausal hormone therapy (MHT) is the most effective option for management of VMS and genitourinary symptoms, some women are unable to use MHT, for personal or health reasons.
RACGP Activity No 796846 – Hours 1
Access to this course is $22.00 (GST INC) by payment through PayPal.
Note: You do not require a PayPal account as the process accepts major credit cards.
AMS Members are pre-enrolled.
This recording will focus on midlife women's
health issues down under. Watch a discussion on the fundamentals of menopause
medicine, management of bleeding whilst on menopausal hormonal therapy, pelvic
floor dysfunction and incontinence, and management of genitourinary syndrome of
the menopause. There will be a panel discussion on managing complex cases.
The workshop is
aimed at all GPs, specialists and allied health workers who are seeking
a comprehensive update in the field of menopause management.
The workshop is
aimed at all GPs, specialists and allied health workers who are seeking
a comprehensive update in the field of menopause management.
Perimenopause: In this webinar, Gynaecologist Professor Rod Baber and GP Dr Karen Magraith explore the clinical issues and management challenges that arise during perimenopause. 
This webinar is targeted at GPs, endocrinologists, gynaecologists, pharmacists and other healthcare professionals. This presentation will include a review of basic female androgen physiology, when it is appropriate to prescribe testosterone for women as well as how to prescribe testosterone for women. Case studies were presented, as well as questions answered.
Menopause: The hot topics will review
the evidence on the safety and key clinical
characteristics of Menopausal Hormone
Therapy (MHT), placing these into context
with up-to-date data, real-life case studies
and an interactive discussion.
The workshop is aimed at all
GPs, specialists and allied health workers who are seeking a
comprehensive update in the field of menopause management.
The workshop is aimed at all GPs, specialists and allied health
workers who are seeking a comprehensive update in the field of menopause
management.
All
major world menopause guidelines are now consistent with advice that MHT is
appropriate treatment to offer to symptomatic healthy women “around the time of
menopause”. This presentation will focus on the practicalities of the menopause
consultation in 2018 and on how to approach the prescribing of MHT in an
individual woman. How to choose, initiate and monitor the different forms of
MHT will be discussed and will include the newer preparations of MHT available
as options in Australia and New Zealand.
Many
factors contribute to female sexual function, which changes with age and in the
years surrounding menopause. Female sexual dysfunction is prevalent and
associated with distressing symptoms that can challenge relationships and
hamper quality of life and wellbeing. The most common type of female
sexual dysfunction is lowered sexual desire. Contributing factors to female
sexual dysfunction are highlighted, with a focus on those relevant to peri- and
postmenopausal women. Assessment and management of women with female sexual
dysfunction is discussed, including the role of menopausal hormone therapy,
testosterone and other targeted treatments. New and emerging treatments
are outlined.
With
the plentiful free press commentary on transvaginal mesh and tapes this session
allows an excellent opportunity to review the management of female urinary
incontinence.
Menopausal hormone therapy (MHT)
is an effective treatment that can be offered to most women with
menopausal symptoms, following an appropriate assessment and using a
shared decision-making process.